The global patient-derived xenografts/PDX models market size was estimated at USD 612.4 million in 2025 and is predicted to increase from USD 696.91 million in 2026 to approximately USD 2230.79 million by 2035, expanding at a CAGR of 13.8% from 2026 to 2035. The market is growing steadily due to increasing demand for personalized cancer therapies and more accurate preclinical drug testing methods. Rising investments in oncology research, along with expanding pharmaceutical and biotechnology pipelines, continue to support market expansion.
Patient-derived xenograft/ PDX models are research models created by implementing human tumor tissue into mice to study cancer behavior and test potential treatments. The patient-derived xenografts/PDX models market is growing rapidly due to increasing demand for personalized cancer treatments and reliable preclinical testing methods. Pharmaceutical and biotechnology companies are widely adopting PDX models to improve drug development success rates and reduce clinical trial failure. Growing cancer prevalence, rising oncology research investments, and advancements in translational medicine are further accelerating market expansion worldwide.
Artificial intelligence is transforming the market by improving tumor analysis, drug response prediction, and biomarker identification. AI-powered data analytics helps researchers process complex genomic and treatment data faster, enabling more accurate and personalized cancer therapy development. The integration of AI also accelerates drug discovery timelines, enhances research efficiency, and supports better decision-making in preclinical oncology studies.
| Table | Scope |
| Market Size in 2026 | USD 696.91 Million |
| Projected Market Size in 2035 | USD 2230.79 Million |
| CAGR (2026 - 2035) | 13.8% |
| Leading Region | North America by 43% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Model Type, By Tumor Type, By Application, By End User, By Host Type, By Implementation Type, By Service Type, By Region |
| Top Key Players | Charles River Laboratories, The Jackson Laboratory, Crown Bioscience, Altogen Labs, Envigo (Inotiv), WuXi AppTec, Oncodesign Services |
| Segment | Share 2025 (%) |
| Mouse-Based PDX Models | 82% |
| Rat-Based PDX Models | 11% |
| Other Animal-Based PDX Models | 7% |
The Mouse-based PDX Models Segment Dominated the Patient-Derived Xenografts/PDX models Market in 2025
The mouse-based PDX models segment held a dominant share of 82% in 2025 due to its high reliability, strong compatibility with human tumor transplantation, and widespread use in oncology research. These models closely replicate human cancer biology, making them highly effective for drug efficacy and biomarker studies. Their cost-effectiveness, established research protocols, and increasing adoption by pharmaceutical and biotechnology companies further contribute to their leading market position.
The rat-based PDX models segment held the second-largest share of 11% in 2025 and is expected to grow at the fastest CAGR in the patient-derived xenografts/PDX models market during the forecast period due to its larger body size, which allows easier surgical procedures, better tumor monitoring, and improved sample collection. These models are increasingly used in complex oncology and pharmacology studies where larger physiological systems are beneficial. Growing research applications, improved translational relevance, and rising demand for advanced preclinical testing models are further supporting segment growth.
| Segment | Share 2025 (%) |
| Gastrointestinal Cancer | 24% |
| Lung Cancer | 20% |
| Breast Cancer | 17% |
| Hematological Cancer | 12% |
| Gynecological Cancer | 9% |
| Prostate Cancer | 7% |
| Brain Tumor | 5% |
| Melanoma | 3% |
| Others | 3% |
The Gastrointestinal Cancer Segment Led the Market in 2025 with the Largest Share
The gastrointestinal cancer segment led the patient-derived xenografts/PDX models market with a share of 24% in 2025 due to led the market with a share of 24% in 2025 due to the increasing global prevalence of colorectal, gastric, and pancreatic cancers. PDX models are widely used in gastrointestinal oncology research because they accurately replicate tumor characteristics and treatment responses. Growing demand for targeted therapies, rising clinical research activities, and expanding investments in precision oncology further supported the segment’s dominant market expansion.
The lung cancer segment held the second-largest share of 20% in 2025 due to its high global incidence and strong research focus on improving treatment outcomes. PDX models are widely used in lung cancer studies to evaluate drug resistance and tumor progression. Increasing prevalence of non-small cell lung cancer, rising clinical trials, and demand for targeted therapies further drive segment growth.
The breast cancer segment held a 17% of market share due to its high global prevalence and increasing need for effective personalized treatment strategies. PDX models are widely used to study tumor heterogeneity, drug resistance, and treatment response in breast cancer research. Rising oncology drug development, expanding clinical trials, and growing focus on precision medicine further support segment expansion.
The hematological cancer segment held 12% share in 2025 and is expected to grow at the fastest CAGR in the patient-derived xenografts/PDX models market during the forecast period due to the increasing incidence of blood-related cancer, such as leukemia, lymphoma, and multiple myeloma. PDX models are highly valuable for studying complex tumor biology and treatment resistance in these cancers. Rising demand for advanced immunotherapy research and improved preclinical testing methods further support strong future growth.
| Segment | Share 2025 (%) |
| Drug Discovery & Development | 41% |
| Personalized Medicine | 22% |
| Basic Cancer Research | 15% |
| Translational Research | 13% |
| Co-Clinical Trials | 9% |
The Drug Discovery & Development Segment Led the Patient-Derived Xenografts/PDX Models Market in 2025 with the Largest Share
The drug discovery & development segment held a dominant share of 41% in 2025 due to its critical role in evaluating drug efficacy and safety in early-stage research. PDX models closely mimic human tumour biology, making them highly valuable for identifying promising oncology drugs. Increasing R&D investments by pharmaceutical companies, rising demand for accurate preclinical testing, and efforts to reduce clinical failure drive segment dominance.
The personalized medicine segment held the second-largest share of 22% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to rising demand for patient-specific cancer treatment approaches. PDX models help researchers evaluate how individual tumors respond to different therapies, improving treatment selection accuracy. Growing focus on precision oncology, increasing biomarker-driven studies, and expanding adoption of tailored therapies in cancer care further support the strong growth of this segment.
The basic cancer research segment held a 15% of patient-derived xenografts/PDX models market share due to increasing efforts to understand tumor biology, cancer progression, and treatment resistance. PDX models provide highly accurate human tumor representation, making them valuable for foundational studies. Rising academic research activities, growing oncology funding, and expanding collaboration between research institutes and pharmaceutical companies further drive the segment’s growth.
The translational research segment held a 13% of market share due to its crucial role in bridging laboratory findings with clinical applications. PDX models closely replicate human tumor behavior, enabling effective testing of drug response before clinical trials. Increasing focus on precision oncology, rising collaboration between academic and industry researchers, and growing demand for faster drug development are driving strong segment growth.
| Segment | Share 2025 (%) |
| Pharmaceutical & Biotechnology Companies | 46% |
| Contract Research Organizations (CROs) | 28% |
| Academic & Research Institutes | 19% |
| Hospitals & Diagnostic Centers | 7% |
The Pharmaceutical & Biotechnology Companies Segment Led the Market in 2025 with the Largest Share
The pharmaceutical & biotechnology companies segment dominated the patient-derived xenografts/PDX models market with a share of 46% in 2025 due to their heavy reliance on advanced data analytics, clinical trial monitoring, and precision research operations. These organizations generate large volumes of complex biomedical data that require centralized command systems for real-time tracking and decision-making. Increasing investment in drug discovery, biologics development, and AI-driven research workflows further strengthens their dominance in adopting healthcare command center solutions.
The contract research organizations (CROs) segment held the second-largest share of 28% in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to the rising outsourcing of clinical trials by pharmaceutical and biotechnology companies. CROs rely heavily on the command center systems to manage complex multi-site studies, ensure real-time data tracking, and improve trial efficiency. Increasing global clinical research activity, cost optimization needs, and demand for faster drug development timelines are further strengthening CRO adoption of advanced healthcare command center solutions.
The academic & research institutes segment held a 19% of patient-derived xenografts/PDX models market share due to increasing focus on medical innovation, translational research, and data-driven clinical studies. These institutions are adopting healthcare command center solutions to manage large research datasets, monitor clinical trials, and improve collaborations across departments. Rising government funding, partnership with health providers, and growing emphasis on AI-enabled research and precision medicine are further accelerating adoption in this segment.
The hospitals & diagnostics centers segment held a 7% of market share due to increasing patient admissions, rising prevalence of chronic diseases, and growing demand for timely and accurate diagnoses. These facilities are adopting healthcare command center solutions to improve patient flow, optimize resource utilization, and enhance diagnostic efficiency. Integration of AI-based imaging, real-time monitoring systems, and digital health platforms is further supporting operational efficiency and accelerating growth in this end-user segment.
| Segment | Share 2025 (%) |
| Model Development | 31% |
| Model Characterization | 19% |
| Drug Efficacy Testing | 24% |
| Cryopreservation & Biobanking | 14% |
| Molecular Profiling Services | 12% |
The Model Development segment led the Market in 2025 with the Largest Share
The model development segment led the patient-derived xenografts/PDX models market with a share of 31% in 2025 due to rising demand for predictive analytics, AI-driven decision support, and customized healthcare algorithms. Hospitals and healthcare organizations are increasingly relying on advanced models to forecast patient flow, optimize resource allocation, and improve clinical outcomes. Continuous innovation in machine learning, data integration, and real-time analytics is further strengthening the need for robust mode development services in healthcare command center solutions.
The drug efficacy testing segment held the second-largest share of 24% in 2025 and is expected to grow at the fastest CAGR in the patient-derived xenografts/PDX models market during the forecast period, due to increasing demand for faster and more accurate evaluation of drug performance during clinical development. Rising adoption of AI-driven analytics, simulation models, and real-world evidence is improving testing efficiency and reducing trial failure. Growing focus on precision medicine, regulatory pressure for better outcomes, and rising R&D investments in drug development are further accelerating segment growth.
The model characterization segment held 19% share in 2025 and is growing due to increasing demand for accurate validation and performance assessment of predictive healthcare and drug development models. Organizations are focusing on ensuring reliability, precision, and regulatory compliance of AI-driven and statistical models used in clinical research. Rising adoption of machine learning, complex data integration, and personalized medicine approaches is further driving the need for robust model characterization services in healthcare applications.
The cryopreservation & biobanking segment held 14% share in 2025 and is expanding due to rising demand for long-term storage of biological samples used in research, drug discovery, and precision medicine. Increasing clinical trials, growth in regenerative medicine, and advancements in cell and gene therapy are boosting the need for high-quality sample preservation. Improved storage technologies, strict regulatory standards, and growing investments in biorepositories are further accelerating segment expansion.
North America dominated the market with a share of 43% in 2025 due to its strong presence of advanced pharmaceutical and biotechnology companies, well-established research infrastructure, and high investment in oncology drug development. Increasing prevalence of cancer, rising demand for personalized medicine, and widespread adoption of preclinical testing models further support market leadership. Additionally, strong academic-industry collaborations and advanced laboratory technologies continue to drive regional dominance.
U.S. Market Trends
The U.S. leads the patient-derived xenografts/PDX models market due to its strong biotechnology ecosystems, advanced cancer research infrastructure, and high R&D investments in oncology drug development. The presence of leading pharmaceutical companies, CROs, and academic institutes supports the rapid adoption of PDX models for precision medicine and drug screening. Rising cancer burden, strong funding support, and continuous innovation in preclinical testing technologies further strengthen U.S. market dominance.
Asia Pacific held 21% share of the patient-derived xenografts/PDX models market in 2025 and is expected to grow at the fastest CAGR in the market during the forecast period due to rapidly expanding healthcare infrastructure, increasing cancer prevalence, and rising investment in biomedical research. Growing pharmaceutical outsourcing activities, expanding CRO presence, and supportive government funding for precision medicine are further accelerating adoption. Additionally, cost-effective research services and increasing clinical trial activities are boosting regional market growth during the forecast period.
India Market Trends
India is expected to grow at the fastest CAGR in the patient-derived xenografts/PDX models market due to the rapid expansion of healthcare infrastructure, increasing burden of chronic diseases, and rising demand for advanced drug development and clinical research services. The growing presence of CROs, cost-effective research capabilities, and strong government support for biotechnology and precision medicine are further boosting growth. Additionally, increasing pharmaceutical outsourcing and clinical trial activities are accelerating market expansion in India.
R&D:
Clinical Trials & Regulatory Approvals:
Patient Support & Services:
| Companies | Headquarters | Offerings |
| Charles River Laboratories | Massachusetts, USA | Large PDX tumor libraries, in vivo oncology testing, translational cancer research models, and drug efficacy evaluation services. |
| The Jackson Laboratory | Bar Harbor, Maine, USA | Provides mouse models, PDX systems, tumor biology research platforms, and precision oncology testing tools. |
| Crown Bioscience | California, USA | Delivers extensive PDX model platforms, immuno-oncology testing, biomarker research, and preclinical oncology services. |
| Altogen Labs | Texas, USA | Focuses on PDX model development, xenograft studies, and in vivo cancer drug testing for preclinical research. |
| Envigo (Inotiv) | Indiana, USA | Provides laboratory animal models, PDX and xenograft services, and toxicology and safety testing support. |
| WuXi AppTec | Shanghai, China | Offers integrated drug development services, including PDX models, oncology screening, and preclinical research support. |
| Oncodesign Services | Dijon, France | Specializes in PDX oncology models, translational pharmacology, and targeted cancer drug evaluation services |
Strengths
Weaknesses
Opportunities
Threats
By Model Type
By Tumor Type
By Application
By End User
By Host Type
By Implementation Type
By Service Type
By Region
Principal Consultant
Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.
Learn more about Shivani Zoting
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
+1 804-441-9344
